Mineralys Therapeutics (MLYS) EBITDA
Market Cap: $738.98M
Avg Volume: 1.02M
Industry: Biotechnology
Sector: Healthcare
What is Mineralys Therapeutics's EBITDA?
- Mineralys Therapeutics's annual EBITDA is $-192.40M.
- Mineralys Therapeutics's quarterly EBITDA is $-51.75M.
What is EBITDA?
EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a measure of a company's overall financial performance and is used as an alternative to net income in some circumstances.
How is EBITDA calculated?
EBITDA is calculated using the following formula:
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
Related Metrics
Other important metrics to assess Mineralys Therapeutics's financial health include:
- EBITDA Ratio - measures the company's EBITDA as a percentage of its revenue:
- Annual: -
- Quarterly: -
- Growth EBITDA - measures the annual growth rate of the company's EBITDA:
- Annual: -127.27%
- Quarterly: 13.88%
- Growth EBITDA Ratio - measures the annual growth rate of the company's EBITDA ratio:
- Annual: 0.00%
- Quarterly: 0.00%
These metrics provide insights into Mineralys Therapeutics's financial health and its ability to meet short-term obligations. Comparing these ratios with industry benchmarks can offer a deeper understanding of the company's performance.
Annual EBITDA
$-192.40M
Quarterly EBITDA
$-51.75M
Mineralys Therapeutics Historical EBITDA
Historical EBITDA Ratio (Annual)
Historical EBITDA Ratio (Quarterly)
Mineralys Therapeutics Historical EBITDA Metrics
The table below shows various financial metrics for each year, with the latest data available for the last fiscal year 2024.
| Year | EBITDA | Growth EBITDA | EBITDA Ratio | Growth EBITDA Ratio |
|---|---|---|---|---|
| 2024 | $-192.40M | -127.27% | - | 0.00% |
| 2023 | $-84.66M | -168.93% | - | 0.00% |
| 2022 | $-31.48M | 0.00% | - | 0.00% |
| 2021 | $- | 0.00% | 0.00% | 0.00% |
| 2020 | $- | 0.00% | 0.00% | 0.00% |
Related Metrics
Explore detailed financial metrics and analysis for MLYS.